Patients with CD4 + naïve/memory ratio ≥0.36 had a poorer OS than those with CD4 + naïve/memory ratio <0.36 (P = 0.021). In addition, CD4 + naïve/memory ratio showed independent prognostic impact (HR 1.427, 95% CI 1.033-1.973, P = 0.031).
Patients with CD4 + naïve/memory ratio ≥0.36 had a poorer OS than those with CD4 + naïve/memory ratio <0.36 (P = 0.021). In addition, CD4 + naïve/memory ratio showed independent prognostic impact (HR 1.427, 95% CI 1.033-1.973, P = 0.031).
Furthermore, poorer clinical response was correlated with higher level of CD8 + naïve/ memory ratio after the third cycle of chemotherapy (P = 0.01). Besides, patients with a lower level of CD8 + naïve/memory ratio had longer progression-free survival (PFS) (P = 0.028). We propose CD4 + naïve/memory ratio as a novel prognostic biomarker
| INTRODUCTION
Pancreatic cancer is a highly lethal malignancy with an overall 5-year survival of approximately 6%. 1 In a world
Health Organization (WHO) survey of global cancer statistics in 2012, it ranks the 7th leading cause of cancerrelated mortality. 2 Despite the progress in the strategies of diagnosis and therapy, the prognosis for pancreatic cancer patients remains extremely dismal. 3 Therefore, it is of great significance to identify novel biomarkers to improve outcome for patients with pancreatic cancer by assisting precise decision-making and allowing individual risk stratification. Dysregulation in cancer patient's immune system is one of hallmarks of cancer. 4 Considerable evidence reveals that the host immune reaction plays a pivotal role in both inhibition and promotion of cancer growth. 5 This pivotal immune function involves both naïve T cells and memory T cells.
for APC. In addition, CD8 + naïve/memory ratio can be a candidate marker for predicting PFS and the change of its level may reflect the progression of APC. Naïve T cells express CD45RA and are usually functionally quiescent 6 ; but in responses to stimuli, they may produce a high level of chemokines, such as CXCL8, which mediates neutrophil migration to a tumor and promotes tumor growth. 7 In contrast, memory T cells are of the CD45RO + phenotype, 8 and secrete IFN-γ, CCL4, XCL1 and other cytokines to kill tumor cells directly or indirectly. 9, 10 In previous studies, changes in both naïve and memory T cells in solid tumors were shown to have prognostic impact, but their prognostic role in pancreatic cancer stay elusive. [11] [12] [13] [14] [15] [16] For example, in 2011, Fogar et 
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| Flow cytometry for lymphocyte subset analyses
A routine clinical flow cytometry test protocol was followed for evaluation of lymphocytes in the peripheral blood. Briefly, 100uL whole blood was added into a tube and cells were blocked with 2.5 µg of Human BD Fc Block for 10 min and then stained with antibodies in PBS containing 0.1% (wt/ vol) BSA and 0.1% NaN3. The following antibodies were purchased from BD Biosciences (San Jose, CA, USA): anti-CD4 (RPA-T4), anti-CD8 (RPA-T8), anti-CD45RA (HI100), anti-CD45RO (UCHL1). Then, 2 mL 1X RBC Lysis Buffer (Biolegend, 420301) were added into the samples. After incubation for 10-15 min at room temperature, cells were collected by centrifugation at 270 g for 5 min and resuspended in FACS staining buffer. The FCM data were acquired on a BD FACSCanto and data were analyzed by using BD FACSDiva flow cytometry analysis software. The representative images 
| Statistical analysis
The statistical analyses were conducted with SPSS statistical software (version 21.0; SPSS Inc, IBM, Armonk, NY, USA). The Pearson's correlation coefficient was used to evaluate the strength of the linear relationships among naïve, memory T cells and clinicopathological variables. The Kaplan-Meier analysis was conducted to assess the prognosis and the log rank test was used to compare the survival between groups.
In Kaplan-Meier analysis, the cut-off value of CD4 + or CD8 + naïve/memory T cells and their ratios were identified as the median level of these variables. The Cox regression model was used to investigate the independent prognostic variables. The correlation of naïve/memory T cells in response to firstline chemotherapy was assessed with the two-tailed Student's t test. Progression-free survival is defined as the time from the initiation of the first-line chemotherapy to the earlier of death or disease progression. In addition, Kaplan-Meier analysis was used to evaluate the PFS in different groups. Two-sided P < 0.05 was considered statistically significant in all tests.
| RESULTS
| Patient characteristics
The majority of patients were male (63.5%) and the median age was 60 (range 36-81) years. Most of patients have distant 
| Circulating naïve/memory T cells and their correlation
The distribution of circulating CD4 + or CD8 + naïve/memory T cells was shown in Table 1 . 
| Interrelationships between clinicopathological variables
We analyzed the interrelationships between CD4 + and CD8 + naïve/memory T cells and other clinicopathological variables of APC ( 
| Prognostic impact of naïve and memory T cells
Kaplan-Meier analyses revealed that patients with CD4 + CD45RO + /CD4 + (%) ≥70.5 seemed to have a better OS compared to those with CD4
<70.5 (P = 0.036, Figure 3B ). In addition, patients with CD4 + naïve/memory ratio ≥0.36 had a poorer OS compared to those with CD4 + naïve/memory ratio <0.36 (P = 0.021, Figure 3C ). However, no significant difference in survival was found in high or low CD4 + CD45RA + /CD4 + (%) group ( Figure 3A ). In addition, there was also no association between CD8 + CD45RA + /CD8 + (%), CD8 + CD45RO + /CD8 + (%), CD8 + naïve/memory ratio and survival.
| Multivariate analysis: independent prognostic value of CD4 + naïve/memory ratio
All significant demographic and clinicopathological factors, including Eastern Cooperative Oncology Group (ECOG PS), distant metastasis, carbohydrate antigen 19-9 (CA19-9) log value, CD4 + naïve/memory ratio and ANC, from the univariate analysis were incorporated into the multivariate Cox regression model ( Table 3 ). The former four were independent prognostic factors. Among them, CD4 + naïve/memory ratio showed independent prognostic impact (HR 1.427, 95% CI 1.033-1.973, P = 0.031).
| Dynamics of naïve/memory T cells and its correlation with first-line treatment
To investigate the correlation of percent of naïve/memory T cells with response to first-line treatment, we collected the blood of 12 APC patients before the first, second and third cycle and after the third cycle of first-line chemotherapy ( Figure 4) . All Figure 5F ).
| The correlation between naïve/memory T cells and PFS
Patients with a low level of CD8 + CD45RA + /CD8 + (%) had a better PFS than high level (median PFS 4.2 vs 2.8 months, P = 0.027, Figure 6D ). In contrast, elevated CD8 + CD45RO + /CD8 + (%) predicted better PFS (median PFS 3.9 vs 2.8 months, P = 0.044, Figure 6E ). Besides, Kaplan-Meier analysis revealed that patients with a lower level of CD8 + naïve/memory ratio had longer PFS (median PFS 4.2 vs 2.8 months, P = 0.028, Figure 6F ). 
| DISCUSSION
Pancreatic cancer is an immunogenic tumor correlated with various kinds of immune/inflammatory cells. Among them, previous studies showed that both naïve T cells and memory T cells played a pivotal role in pathogenesis but their role in pancreatic cancer progression remains elusive. 7 Thus, we try to investigate the clinical implication of CD4 + /CD8 + naïve and memory T cells in APC patients. In this study, we found a novel association between the percent of CD4 + naïve T cells and CD8 + naïve T cells, CD4 + memory T cells, and CD8 + memory T cells. In addition, both CD4 + naïve/memory ratio and CD8 + naïve/memory ratio showed close correlations with hemoglobin and RBC. The baseline level of hemoglobin and RBC usually reflect the nutrition status of patients with APC and is found to be correlated with prognosis. 20 As immunonutrition can suppress the inflammatory response, it is reasonable that there are positive correlation between hemoglobin, RBC, and naïve/memory ratio. 21 As we described before, both naïve and memory T cells showed their prognostic impact in various tumors but have not been extensively explored in pancreatic cancer. In our study, better OS (P = 0.036 and 0.021, respectively). In addition, among these 6 immune parameters, only CD4 + naïve/memory ratio showed independent prognostic impact in multivariate analysis (HR 1.427, 95% CI 1.033-1.973, P = 0.031). Intriguingly, Peng Yang et al also found similar result in nonsmall cell lung cancer that elevated CD4 + naïve/memory ratio, rather than the other five immune parameters, correlated with prolonged progression-free survival (P = 0.013). 22 These results suggested that the ratio, rather than absolute count of naïve and memory T cells was more suitable to reveal the systemic inflammatory response to cancer. This may be explained by the fact the absolute count of different phenotypes of T cells are also affected by other factors, such as age, to different extent. 8 For instance, previous studies demonstrated that there was an increase in the number of circulating memory T cells, especially CD4 + memory T cells over time. 23, 24 Evidence also showed that naïve T cells were negatively correlated or even decreased with age. 24, 25 The efficacy and prediction of resistance to chemotherapy in patients with APC are essential to prolong PFS and further improve prognosis. Recent studies revealed that inflammatory cells might affect the component of the pancreatic stroma to affect the progression of pancreatic cancer. The levels of CD3, CD4, CD8, CD68, and CD206 expression + (E), and CD8 + naïve/memory ratio (F) are shown for samples taken before the first, second, and third cycle and after the third cycle of first-line chemotherapy. Abbreviation: c1, before cycle 1; c2, before cycle 2; c3, before cycle 3; ac3, after cycle 3; SD, stable disease; PD, progressive disease in pancreatic cancer were found to be independently correlated with tumor recurrence by immunohistochemistry. 26 In addition, during clinical management, chemotherapy was found to be associated with long-term changes in different phenotypes of circulating lymphocyte levels. 11, 27 In this study, we demonstrated that the low level of CD8 + naïve/memory ratio after the third cycle of first-line chemotherapy was correlated with improved clinical response (SD vs PD: 0.87 ± 0.13 vs 2.76 ± 0.69, P = 0.01 The data are demonstrated as the mean ± SEM and the P values are determined by the Student's t test (* SD compared with PD, P < 0.05). Abbreviation: c1, before cycle 1; c2, before cycle 2; c3, before cycle 3; ac3, after cycle 3; NS, not significant; SD, stable disease; PD, progressive disease may reflect the progression of pancreatic cancer in a better way than other variables. There are several limitations of this study. First, the sample size of the patients, in whom the change of percent of naïve/memory T cells during first-line treatment was investigated, was not large enough to reach definitive conclusions, which calls for further larger-scale studies. Second, there are three major subsets of memory T cells in the blood: stem cell memory T cells, central memory T cells (T CM ) and effector memory T cells (T EM ), which have different properties and capacities. 8 Because of its design, our work cannot solve the question of difference in clinical impact of specific phenotype of memory T cells on pancreatic cancer. Third, an external validation cohort is still needed in the future to make the result more convincing.
In conclusion, we found that CD4 + naïve/memory ratio can be a novel prognostic biomarker for advanced pancreatic cancer. In addition, CD8 + naïve/memory ratio can be a candidate marker for predicting PFS and its change may reflect the progression of APC.
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